Oxaliplatin, Fludarabine, and Cytarabine in Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndromes (MDS)
Status:
Terminated
Trial end date:
2010-08-01
Target enrollment:
Participant gender:
Summary
The goal of this clinical research study is to find the highest tolerable dose of oxaliplatin
combined with fludarabine plus cytarabine that can be given to patients with Acute Myeloid
Leukemia (AML) or High-Risk Myelodysplastic Syndromes (MDS). Once the highest tolerable dose
of oxaliplatin in this drug combination is found, the next goal of the study will be to learn
the safety and the ability of the drug combination to control the disease.